查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1122569

心臟定位的全球市場預測(2022年～2027年)

Global Cardiac Mapping Market - Forecasts from 2022 to 2027
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 147 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球心臟定位的市場規模預測將從2020年的7億8,050萬1,000美元，2027年達到18億2,816萬7,000萬美元，以年複合成長率12.93％增長。

隨著不健康的生活方式導致心臟相關疾病的增加，個人接受更頻繁的健康檢查，並選擇適當和有效的心臟健康檢查和 EP 測試。預計手機和設備的普及將推動預測期內市場增長。

本報告提供全球心臟定位市場相關調查分析，提供市場動態，各市場區隔的市場分析，競爭環境，主要企業等資訊。

目錄

第1章 簡介

  • 市場概要
  • COVID-19影響
  • 市場定義
  • 市場區隔

第2章 調查手法

  • 調查資料
  • 前提

第3章 摘要整理

  • 調查的重點

第4章 市場動態

  • 推動市場要素
  • 阻礙市場要素
  • 波特的五力分析
    • 供給企業談判力
    • 買方議價能力
    • 新加入廠商業者的威脅
    • 替代品的威脅
    • 產業的競爭情形
  • 產業價值鏈分析

第5章 全球心臟定位市場分析:各產品

  • 簡介
  • EP心導管電氣燒灼術
  • EP實驗設備
  • EP診斷導管
  • 存取(點閱)設備

第6章 全球心臟定位市場分析:各適應症

  • 簡介
  • 心房顫動
  • 心房撲動
  • 房室結迴旋性心搏過速
  • 沃爾夫-巴金森-懷特氏症候群

第7章 全球心臟定位市場分析:各終端用戶

  • 簡介
  • 醫院·診療所
  • 診斷中心

第8章 全球心臟定位市場:各地區

  • 簡介
  • 北美
    • 北美的心臟定位市場分析:各產品(2020年～2027年)
    • 北美的心臟定位市場分析:各適應症(2020年～2027年)
    • 北美的心臟定位市場分析:各終端用戶(2020年～2027年)
    • 各國
  • 南美
    • 南美的心臟定位市場分析:各產品(2020年～2027年)
    • 南美的心臟定位市場分析:各適應症(2020年～2027年)
    • 南美的心臟定位市場分析:各終端用戶(2020年～2027年)
    • 各國
  • 歐洲
    • 歐洲心臟定位市場分析:各產品(2020年～2027年)
    • 歐洲心臟定位市場分析:各適應症(2020年～2027年)
    • 歐洲心臟定位市場分析:各終端用戶(2020年～2027年)
    • 各國
  • 中東·非洲
    • 中東·非洲的心臟定位市場分析:各產品(2020年～2027年)
    • 中東·非洲的心臟定位市場分析:各適應症(2020年～2027年)
    • 中東·非洲的心臟定位市場分析:各終端用戶(2020年～2027年)
    • 各國
  • 亞太地區
    • 亞太地區的心臟定位市場分析:各產品(2020年～2027年)
    • 亞太地區的心臟定位市場分析:各適應症(2020年～2027年)
    • 亞太地區的心臟定位市場分析:各終端用戶(2020年～2027年)
    • 各國

第9章 競爭環境與分析

  • 主要企業策略分析
  • 新興企業與市場盈利
  • 合併·收購·契約·聯盟
  • 供應商的競爭力矩陣

第10章 企業簡介

  • Biosense Webster, Inc.
  • Medtronic
  • Abbott
  • BIOTRONIK SE & Co KG
  • Acutus Medical
  • Baylis Medical Company, Inc.
  • Boston Scientific Corporation
簡介目錄
Product Code: KSI061613782

The global cardiac mapping market is projected to grow at a CAGR of 12.93% to reach US$1,828.167million by 2027, from US$780.501 million in 2020.

Atrial fibrillation is a serious growing condition that affects the heart, and the major causes include an unhealthy lifestyle that many individuals lead. According to the American Heart Association, about 2.3 million people in the United States alone suffer from atrial fibrillation. This problem significantly increases the risk of having getting a stroke. Moreover, according to the statistical data provided by the NHS (National Health Service), arrhythmia is a problem that is also known as a heart rhythm problem and is approximately faced and experienced by more than 2 million people a year in the UK. The most common types of arrhythmia that people suffer from include atrial fibrillation, in which the heart beats at an irregular and faster than normal pace. One of the reasons that can result in atrial fibrillation is the consumption of high amounts of alcohol or unhealthy eating habits, such as a diet with high levels of fats and cholesterol, which tend to block the arteries. Therefore, these factors lead individuals to go for health checkups more often and opt for proper and effective heart health checkups or EP exams. This leads to an increase in the adoption of cardiac mapping products and devices, thereby augmenting the market growth over the forecast period.

New and E-effective techniques that can successfully treat atrial fibrillation are providing opportunities for the market players they can harness and boost their market position and accelerate market growth.

There are many advancements in and enhanced procures products and techniques coming up to treat the problem of atrial F fibrillation, which is a growing and persistent problem. In March 2020, a clinical trial that uses pulse-field energy to heal patients and poses a novel approach to treating this and achieving more desirable and accurate patient outcomes was published. The trial of this method was conducted by the Heart Rhythm Society (HRS) in 2020 and was also published in Circulation Arrhythmia and Electrophysiology. The test compared the tissue selectivity of the PFA technique over the Radon Frequency ablation (RF) technique. Therefore, groundbreaking tests and findings such as these provide the market players with an opportunity to enhance and upgrade their product lines by adding products catering to this method and contributing e to the market growth over the forecast period.

Cardiac Mapping Industry Product Offerings by Major Market Players in the Cardiac Mapping Market

Furthermore, the interest being shown by the market payers to provide the end-users such as hospitals and diagnostic centres ers with innovative and advanced cardiac mapping products fuels ing the market growth further over the forecast period

Some of the examples of product offerings are as follows:

Biotronik recently announced a collaboration with Acutus Medical to provide a comprehensive service portfolio of electrophysiology, mapping, ablation, and other accessory products to facilitate catheter-based treatment of cardiac arrhythmias. In May 2020, Biotronik announced that they have partnered up with Acutus Medical to provide a comprehensive service portfolio of electrophysiology, mapping, ablation, and some other accessory products to facilitate catheter-based treatment of cardiac arrhythmias. The product is being launched across the regional markets in Europe and Asia. Their product is called the "Acutus AcQMap System. This product is developed with multi-mode mapping capabilities and is a non-contact mapping stem that can facilitate the mapping of unstable and stable rhythms. In addition, it can optimize the treatment of different types of arrhythmia in under 3 minutes.

In October 2019, Baylis Medical, which is considered one of the leading manufacturing companies for cardiology devices to aid the physicians, announced the first use of its new product line called its product, " EPstar Fixed Electrophysiology Catheters.". "The product line includes the "2-French Electrophysiology Catheter", the "6F guiding catheter" for allowing deeper coronary sinus mapping (CS mapping). Furthermore, the EPstar catheters can provide the smallest catheters available for diagnosis in the North American electrophysiology market, allowing physicians to perform the more effective cardiac mapping. In addition, the EPstar catheters can make available the smallest catheters available for the diagnosis available in the North American electrophysiology market, allowing the physicians to carry out more effective cardiac mapping.

The North American region is estimated to hold a significant market share due to the rising geriatric population over the forecast period. The Asia Pacific region is estimated to increase its market share due to the initiatives being taken to improve the medical and healthcare infrastructure of countries such as India.

The North American region is estimated to hold a significant share over the forecast period due to the well-established healthcare industry and the availability of quality healthcare services, coupled with the early adoption of advanced and enhanced medical devices and detection products, which are being made available the market players. In addition, the growing geriatric population and the increased risk posed by heart problems are among other reasons for the rising demand for cardiac mapping in countries such as the US.

The Asia Pacific region is estimated to increase its share over the forecast period due to the initiatives being taken and the investment being made to develop the medical infrastructure in countries such as India to provide better healthcare facilities available to the population.

COVID-19 Impact

The disease outbreak of COVID-19 drives the growth of the cardiac mapping market. Several research studies have been published to provide insight into the downside risk of the pandemic. A research project issued in January 2021 labelled "Cardiac Involvement of COVID-19: A Comprehensive Review" mentioned that COVID-19 can have a substantial impact on patients' cardiovascular systems. COVID-19 fatalities are strongly linked to cardiovascular disease, hypertension, and diabetes. As a result, patients with CVDs must take every precaution against COVID-19, which may necessitate the use of cardiac mapping. Likewise, another research project captioned "Impact of COVID-19 on the Cardiovascular System: A Review of Available Reports" released in October 2020 stated that there is an uptick in high mortality and morbidity suffering from both cardiovascular events and COVID-19. As a result, during treatment, more emphasis should be placed on viral infection-related heart problems. The market for such studies is expected to grow in the future as a result of the need for cardiac mapping as a result of the COVID-19 pandemic.

Recent Developments

January 2022, Medtronic plc, a leading global in healthcare technology, announced an agreement to procure Affera, Inc., a privately-held medical technology-based company in the Boston area. Affera develops and manufactures cardiac mapping and navigation systems.

January 2022, Abbott obtained FDA clearance for its EnSite X EP with EnSite Omnipolar technology. EnSite X EP generates intricate three-dimensional maps of the heart to assist physicians in identifying and treating areas of the heart where unusual rhythms originate.

Segmentation:

  • By Product

EP Ablation Catheters

EP Laboratory Devices

EP Diagnostic Catheters

Access Devices

  • By Indication

Atrial Fibrillation

Atrial Flutter

Atrioventricular Nodal Reentry Tachycardia

Wolff-Parkinson-White Syndrome

  • By End-User

Hospitals and Clinics

Diagnostic Centers

  • By Geography

North America

  • USA
  • Canada
  • Mexico

South America

  • Brazil
  • Argentina
  • Others

Europe

  • UK
  • Germany
  • France
  • Spain
  • Others

Middle East and Africa

  • Saudi Arabia
  • UAE
  • Israel
  • Others

Asia Pacific

  • Japan
  • China
  • India
  • South Korea
  • Thailand
  • Indonesia
  • Taiwan
  • Others

TABLE OF CONTENTS

1. Introduction

  • 1.1. Market Overview
  • 1.2. COVID-19 Impact
  • 1.3. Market Definition
  • 1.4. Market Segmentation

2. Research Methodology

  • 2.1. Research Data
  • 2.2. Assumptions

3. Executive Summary

  • 3.1. Research Highlights

4. Market Dynamics

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. Global Cardiac Mapping Market Analysis, By Product

  • 5.1. Introduction
  • 5.2. EP Ablation Catheters
  • 5.3. EP Laboratory Devices
  • 5.4. EP Diagnostic Catheters
  • 5.5. Access Devices 

6. Global Cardiac Mapping Market Analysis, By Indication

  • 6.1. Introduction
  • 6.2. Atrial Fibrillation
  • 6.3. Atrial Flutter
  • 6.4. Atrioventricular Nodal Reentry Tachycardia
  • 6.5. Wolff-Parkinson-White Syndrome 

7. Global Cardiac Mapping Market Analysis, By End-User

  • 7.1. Introduction
  • 7.2. Hospitals and Clinics
  • 7.3. Diagnostic Centres

8. Global Cardiac Mapping Market Analysis, by Geography

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. North America Cardiac Mapping Market Analysis, By Product, 2020 to 2027
    • 8.2.2. North America Cardiac Mapping Market Analysis, By Indication, 2020 to 2027
    • 8.2.3. North America Cardiac Mapping Market Analysis, By End-User, 2020 to 2027
    • 8.2.4. By Country
      • 8.2.4.1. United States
      • 8.2.4.2. Canada
      • 8.2.4.3. Mexico
  • 8.3. South America
    • 8.3.1. South America Cardiac Mapping Market Analysis, By Product, 2020 to 2027
    • 8.3.2. South America Cardiac Mapping Market Analysis, By Indication, 2020 to 2027
    • 8.3.3. South America Cardiac Mapping Market Analysis, By End-User, 2020 to 2027
    • 8.3.4. 2027
    • 8.3.5. By Country
      • 8.3.5.1. Brazil
      • 8.3.5.2. Argentina
      • 8.3.5.3. Others
  • 8.4. Europe
    • 8.4.1. Europe Cardiac Mapping Market Analysis, By Product, 2020 to 2027
    • 8.4.2. Europe Cardiac Mapping Market Analysis, By Indication, 2020 to 2027
    • 8.4.3. Europe Cardiac Mapping Market Analysis, By End-User, 2020 to 2027
    • 8.4.4. By Country
      • 8.4.4.1. UK
      • 8.4.4.2. Germany
      • 8.4.4.3. France
      • 8.4.4.4. Spain
      • 8.4.4.5. Others
  • 8.5. Middle East and Africa
    • 8.5.1. Middle East and Africa Cardiac Mapping Market Analysis, By Product, 2020 to 2027
    • 8.5.2. Middle East and Africa Cardiac Mapping Market Analysis, By Indication, 2020 to 2027
    • 8.5.3. Middle East and Africa Cardiac Mapping Market Analysis, By End-User, 2020 to 2027
    • 8.5.4. By Country
      • 8.5.4.1. Saudi Arabia
      • 8.5.4.2. United Arab Emirates
      • 8.5.4.3. Israel
      • 8.5.4.4. Others
  • 8.6. Asia Pacific
    • 8.6.1. Asia Pacific Cardiac Mapping Market Analysis, By Product, 2020 to 2027
    • 8.6.2. Asia Pacific Cardiac Mapping Market Analysis, By Indication, 2020 to 2027
    • 8.6.3. Asia Pacific Cardiac Mapping Market Analysis, By End-User, 2020 to 2027
    • 8.6.4. By Country
      • 8.6.4.1. Japan
      • 8.6.4.2. China
      • 8.6.4.3. India
      • 8.6.4.4. South Korea
      • 8.6.4.5. Thailand
      • 8.6.4.6. Indonesia
      • 8.6.4.7. Taiwan 
      • 8.6.4.8. Others

9. Competitive Environment and Analysis

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Emerging Players and Market Lucrativeness
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Vendor Competitiveness Matrix

10. Company Profiles 

  • 10.1. Biosense Webster, Inc.
  • 10.2. Medtronic
  • 10.3. Abbott
  • 10.4. BIOTRONIK SE & Co KG
  • 10.5. Acutus Medical
  • 10.6. Baylis Medical Company, Inc.
  • 10.7. Boston Scientific Corporation